UnknownNot Applicable

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

China240 participantsStarted 2021-01-08

Plain-language summary

According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction model for TRC.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Female patients diagnosed with HER2-positive breast cancer treated in our hospital.
✓. Surgical treatment combined with chemotherapy or radiotherapy was completed according to NCCN guidelines, and trastuzumab standard treatment was received for at least half a year.

Exclusion criteria

✕. Patients who have not been properly treated with trastuzumab or have been treated for less than half a year;
✕. Patients who did not receive cardiac function assessment before trastuzumab treatment, during or after treatment;
✕. Patients whose case data were missing or lost to follow-up.

What they're measuring

Cardiac toxicity

Timeframe: 12 months

Cardiac toxicity

Timeframe: 12 months

Cardiac toxicity

Timeframe: 12 months

Cardiac toxicity

Timeframe: 12 months

Trial details

NCT IDNCT04962425

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-01

View on ClinicalTrials.gov More Cardiac Toxicity trials